Summary
- Profile Type
- Technology offer
- POD Reference
- TOFR20250613018
- Term of Validity
- 16 June 2025 - 16 June 2026
- Company's Country
- France
- Type of partnership
- Investment agreement
- Commercial agreement with technical assistance
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A French company is developing a disruptive treatment for particularly resistant tumors based on the first dual therapy nanotherapy amplifiying efficacity and effect of radiotherapy and chemotherapy. The company is seeking different kind of partners in nanomedicine and pharmaceutical field to accelerate its development.
- Full Description
-
A French company is developing a breakthrough innovation in oncology with a patented nanomedicine incorporating a unique dual therapy: a chemotherapy molecule combined with gold nanoparticles.
This combination amplifies the effect of radiotherapy, optimizes the efficacy of chemotherapy and enables tumors to be targeted via intra-tumoral administration, thus limiting side effects for patients. This intelligent nano-object could revolutionize the treatment of particularly resistant solid tumors, such as glioblastoma, pancreatic or prostate cancer.
The company encapsulates gold nanoparticles and chemodrug in a nanocapsule that allows very high and efficient passage into glioblastoma cells. The initial POC in vivo results are very promising in terms of animal survival, the median survival of animals treated with this nanomedicine is equal to that of animals without glioblastoma.
The company is seeking for its development 4 types of partners:
• Pharmaceutical laboratories developing innovative molecules or with molecules that could be optimised in the cargo ship,
• CDMO to manufacture the product in bigger quantities,
• Organisations to cooperate with and possibly in the framework of European projects
• Investors (business angels, family offices, Venture Capital) - Advantages and Innovations
-
The world's only dual-therapy nanomedicine: radioenhancer and chemotherapy molecules
Promising results against aggressive cancer such as glioblastoma and possibility to address quickly other kind of cancers
Limitation of side-effects for patients - Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- Goal 17: Partnerships to achieve the Goal
- IPR status
- IPR granted
Partner Sought
- Expected Role of a Partner
-
Pharmaceutical companies or private laboratories developing innovative molecules for cancer treatment
CDMO to manufacture the product
For EU research and innovation projects : Any organisation with an interest in cancer eg: gliobastoma, pancreatic cancer, prostate cancer, which presents in AI, innovative therapeutic access, safety analysis, co-encapsulation of innovative molecules in chemotherapy, which processes megadata concerning cancer, which proposes medical devices in line with the development made by the French company
Investors : Venture capital, business angels, family offices - Type and Size of Partner
- SME 11-49
- SME <=10
- Big company
- SME 50 - 249
- Type of partnership
- Investment agreement
- Commercial agreement with technical assistance
- Research and development cooperation agreement
Dissemination
- Technology keywords
- 06001003 - Cytology, Cancerology, Oncology
- 06004 - Micro- and Nanotechnology related to Biological sciences
- 06001014 - Neurology, Brain Research
- Market keywords
- 05003001 - Therapeutic services
- 05003005 - Drug delivery and other equipment
- 05005014 - Oncology
- Sector Groups Involved
- Health
- Targeted countries
- All countries